Back to Agenda
[S20] Drug Information on the Pharmacokinetics Section in the Japan Package Insert Can be Evolve Furthermore Attractively?
Session Chair(s)
Seongryul Kim, PHD
Clinical Project Leader, Clinical Development, Otuska Pharmaceutical, Japan
Information of pharmacokinetics in Japan package insert is based on traditional practice so far. Providing DDI information and utilization of modeling and simulation data on Japan package insert is described in the DDI guideline issued in 2018 and Population PK/PD analysis guideline issued in 2019 in Japan. In this session, we will share issues and proposals in such a change and consider collaboration with industry, government and academia for appropriate presentation of drug information based on the latest science, such as the utilization of forest plots on drug interactions and covariates, and the simulation data based on PopPK, PKPD and PBPK.
Speaker(s)
Issues and Proposal on the Pharmacokinetics Section in the Japan Package Insert
Senior Scientist, Clinical Pharmacokinetics & Pharmacometrics, MSD K.K., Japan
Regulatory Guidelines on Provision of Pharmacokinetic Information in Package Inserts of New Drugs
Reviewer, Office of New Drug 4, Pharmaceuticals and Medical Devices Agency (PMDA), Japan
Issues and Expectations of Pharmacokinetics Information in the Japan Package Insert at Medical Field
, The University of Tokyo Hospital, Japan
Have an account?